Feature | March 03, 2015

Data Published for Pivotal Trial for Tryton Side Branch Stent

Results demonstrate reductions in target vessel failure, side branch percent stenosis

Tryton Side Branch Stent, Pivotal IDE, bifurcation stent, bifurcation stent

March 3, 2015 — Tryton Medical Inc. announced that results from the company’s pivotal clinical trial for the Tryton Side Branch Stent were published in the Journal of the American College of Cardiology. The Tryton Pivotal IDE Trial, which enrolled 704 patients at 67 centers in North America and in 11 countries in the European Union and Israel, was the largest coronary bifurcation study ever conducted.

The Tryton Pivotal IDE trial was a randomized study comparing the Tryton Side Branch Stent to conventional provisional treatment with balloon angioplasty in the side branch. Both study groups were treated with standard drug-eluting stents in the main vessel. Among the 704 patients in the study, fully 60 percent of side-branch vessels treated were smaller than 2.25 mm diameter by quantitative coronary arteriography (QCA). The intended population for the trial included patients presenting with side branch vessels of 2.25 mm diameter or greater by QCA.

Researchers reported that while the study did not meet its primary endpoint of non-inferiority in measures of target vessel failure (TVF) in the overall population of patients treated, post-hoc analysis of outcomes in the intended study population of 289 patients with side branch vessels of 2.25 mm diameter or greater by QCA showed reductions in TVF and side branch percent diameter stenosis with the Tryton stent. In addition, both the Tryton and provisional treatment strategies were shown to have similarly low rates of stent thrombosis and no cardiac deaths reported at nine months.

“The most important finding was the performance of the Tryton Stent in the intended population presenting with complex bifurcations involving significant side branches. In this population, Tryton showed a reduction of TVF within the non-inferiority margin pre-specified for the entire population and significantly reduced side branch percent diameter stenosis,” stated Philippe Genereux, M.D., director of the Core Angiographic Laboratories at the Cardiovascular Research Foundation and the lead author of the manuscript.

For more information: www.tryton.medical.com

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Overlay Init